reports
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 29, 2024 to May 3, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 602,818 1,222,541,085.50April 29, 202...
TGS Secures New Ocean Bottom Node Data Acquisition Contract in North A...
TGS Secures New Ocean Bottom Node Data Acquisition Contract in North America OSLO, Norway (6 May 2024) – TGS, a leading global provider of energy data and intelligence, is pleased to announce the award of an Ocean Bottom Node (OBN) data acquisition contract in North America. This six-month-plus contract, granted by a returning client, reinforces TGS' position in the market and underscores its commitment to delivering high-quality seismic data solutions. The project is expected to enhance the client’s seismic data acquisition capabilities, facilitating more informed decision making. ...
Q1 update: Novonesis delivers 4% organic sales growth in line with exp...
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolution...
Trading statement Q1 2024
Trading statement Q1 2024 Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales perfo...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
VOLV B VOLVO AB CLASS B
WRT1V WARTSILA OYJ ABP
ABB ABB LTD.
SAND SANDVIK AB
TREL B TRELLEBORG AB CLASS B
MOCORP METSO OUTOTEC OYJ
ASSA B ASSA ABLOY AB CLASS B
SKF B SKF AB CLASS B
HPOL B HEXPOL AB CLASS B
ALFA ALFA LAVAL AB
MTRS B MUNTERS GROUP
HEXA B HEXAGON AB
EPI A EPIROC AB
NIBE B NIBE INDUSTRIER AB
ATCO A ATLAS COPCO AB
ALIV SDB AUTOLIV INC.
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024
Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.
Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated...
Resolutions from the annual shareholders’ meeting 2024
Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.• Approval of the Remuneration Report fo...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat R...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – (Nasdaq: GMAB) and (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) f...
Transactions in Connection with Share Buy-back Program Genmab
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 22, 2024 to April 26, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 408,701 836,159,5...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
TGS Vesting Under the 2022 Long-Term Incentive Plan
TGS Vesting Under the 2022 Long-Term Incentive Plan Oslo, Norway (29 April 2024) –TGS granted the second tranche of Performance Stock Units (PSUs) under the Magseis 2022 Long-term Incentive Plan previously adopted and authorized by the Board of Directors of TGS ASA in 2023. In accordance with the terms of this Plan, the second tranche of PSUs vested on 1 April 2024, resulting in a total of 61 PSU holders having the right to request the issuance of TGS shares at par value NOK 0.05. The company previously determined that the final payout on the PSUs is 58.3% based on achievement of perfor...
- Tomi Railo
Wärtsilä (Buy, TP: EUR20.00) - Smooth sailing
Following strong Q1 orders and earnings, we have raised our 2024–2026e clean EPS by 4% on average and our target price to EUR20 (18). We reiterate our BUY. We continue to forecast multiyear sales and earnings growth for Wärtsilä, and view it as attractively valued (see our recent report ‘Refuelled engines’).
- Ebba Bjorklid
Husqvarna (Sell, TP: SEK63.00) - Pressure persists
Continued weak end-market demand, lower production volumes, and a legacy-business exit weighed on sales and earnings in Q1. We expect organic growth and earnings to remain under pressure in 2024. Following the Q1 results, we reiterate our SELL and SEK63 target price.
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
- ABGSC IT Research
- Øystein Elton Lodgaard
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
TGS Q1 2024 Presentation and Webcast
TGS Q1 2024 Presentation and Webcast OSLO, Norway (24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. For m...
Transactions in Connection with Share Buy-back Program Genmab
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 15, 2024 to April 19, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 269,334 555,043,478.37Ap...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.